THE PUBLISHING HOUSE
OF THE ROMANIAN ACADEMY

NAVIGATING CONCEPTUAL INTERFERENCES AND SIGNIFICANT MILESTONES IN THE TIMELINE OF DIABETOLOGY: A NARRATIVE REVIEW

Maria-Flavia SUSANU[a,b], Crina-Cristina SOLOMON[c], Alexandru-Silvestru SUSANU[d], Elisabeta RĂDULESCU[e,f], Andreea SĂLCUDEAN[g]*, Raluca-Maria TILINCA[h], Maria Gabriela REZMÜVES[i], Adrienn NEMETH[j] and Mariana Cornelia TILINCA[k,l]

[a]Endocrinology Department, Mureș County Clinical Hospital, 540139 Târgu Mureș, Romania
[b]Department of Scientific Research Methodology, G.E. Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, 540139, Târgu Mures, Romania
[c]Faculty of Medicine, „Lucian Blaga" University, Sibiu, Romania, 550024, România
[d]G.E. Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mures, 540139, Târgu Mureș, Romania
[e]Doctoral School of Biomedical Sciences, "Dunarea de Jos" University, 800008, Galați, Romania
[f]Braila County Emergency Clinical Hospital, 810249, Brăila, Romania
[g]Department of Ethics and Social Sciences, G.E. Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, 540139, Târgu Mureș, Romania
[h]Mureș County Clinical Hospital, 540139 Târgu Mureș, Romania
[i]Internal Medicine Clinic 1, Emergency Clinical County Hospital of Târgu Mureș, 540136, Târgu Mureș, Romania
[j]Emergency Department, Emergency Clinical County Hospital of Târgu Mureș, 540136, Târgu Mureș, Romania
[k]Department of Diabetes, Nutrition and Metabolic Diseases, Emergency Clinical County Hospital of Târgu Mureș, 540136, Târgu Mureș, Romania
[l]Department of Internal Medicine, G.E. Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, 540139, Târgu Mureș, Romania

**Corresponding author:* Andreea SĂLCUDEAN, andreea.salcudean@yahoo.com

Received July 25, 2023

In the realm of diabetology, navigating conceptual interferences presents a critical challenge. Misconceptions and evolving paradigms have hindered a comprehensive understanding of diabetes, while patient variability underscores the need for personalized care. Technological advancements offer enhanced monitoring, but also introduce complexity in data interpretation. Diagnostic challenges arise from overlapping subtypes, necessitating a multidisciplinary approach. Addressing these interferences demands education to dispel misconceptions and foster awareness of evolving classifications. Multidisciplinary collaboration integrates diverse expertise for optimal patient care, and personalized medicine tailors treatments through data-driven insights. Research and innovation are vital for staying ahead of shifting concepts. By embracing a holistic approach that educates, collaborates, personalizes, and innovates, diabetology can overcome these challenges and advance towards improved patient care and scientific progress.

Keywords: diabetes mellitus, diabetes timeline, milestones in the history of diabetes, conceptual interferences in diabetology

INTRODUCTION

Diabetes mellitus, a chronic metabolic disorder characterized by elevated blood glucose levels, affects millions worldwide and demands continuous advancements in research, diagnosis, and treatment.[1] Long-term harm, dysfunction, and failure of various organs, including the eyes, kidneys, nerves, heart, and blood vessels, are linked to the chronic hyperglycemia of diabetes.[1]

Although there have been advancements in treatment, diabetes mellitus is still a chronic, incurable condition.[1] Type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus are the two primary subtypes. Type 1 diabetes is brought on by the immune system attacking the pancreatic islet beta cells, whereas type 2 diabetes is brought on by decreased insulin secretion and resistance to the effects of insulin.[1,2] According to recent epidemiological data, 9% of persons who are 18 years of age or older have diabetes mellitus, and 1.5 million people were thought to have died from the condition in 2012. Diabetes will be the seventh most common cause of death in 2030, according to the World Health Organization.[3,4]

The annals of medical history are replete with tales of discovery, innovation, and perseverance. Among these narratives, the chronicle of diabetes mellitus stands as a compelling testament to the relentless pursuit of knowledge and the evolution of medical understanding. From the mists of antiquity to the cutting-edge laboratories of today, the history of diabetes is a captivating journey that unveils not only the medical progress made but also the intricate interplay between culture, science, and human resilience.

Within the realm of diabetology, an unique challenge arises – conceptual interferences. These interferences often stem from misconceptions, evolving scientific paradigms, multiple new uses of antidiabetic medication and complex patient profiles, posing hurdles to effective patient care and scientific progress.

The aim of this narrative review is to emphasize the existing literature data regarding conceptual interferences in diabetology, highlighting their impact, highlight the history of diabetes mellitus and how the perception of diabetes has changed over the years and propose strategies for better understanding and managing these challenges.

MATERIALS AND METHODS

Using various combinations of keywords, such as “diabetes mellitus”, “diabetes timeline”, “milestones in the history of diabetes” and “conceptual interferences in diabetology”, relevant studies were found using the PubMed search engine. In addition, other articles were found by looking through the reference list of significant publications. Data pertinent to the subject of this research were taken from all reviewed papers, which were all written in English.

RESULTS

LANDMARKS IN THE EVOLUTION OF DIABETES MELLITUS

ANCIENT ORIGINS

The earliest references to a condition similar to diabetes can be found in ancient civilizations. The Ebers Papyrus from 1552 BC documented a mysterious ailment marked by excessive urination and unquenchable thirst, which turned out to be diabetes mellitus. The Greeks also observed the sweetness of diabetic urine and coined the term “diabetes” from the Greek word “siphon”, meaning “to pass through”.[5–7]

Indian surgeon Sushruta described diabetes as “madhumeha” (honey-like urine), characterized by excessive thirst, frequent urination, and sweet-tasting urine. The condition is difficult to treat and can lead to complications over time. Chang Chung-Ching, also known as “the Chinese Hippocrates”, described polyuria, polydipsia, and weight loss as signs of specific diseases. In the seventh century AD, Chen Chuan noted the presence of sweet urine in diabetes mellitus and named the condition “Hsiao kho ping”. To manage the illness, Li Hsuan suggested avoiding alcohol, salt, and sexual activity.[5–7]

MIDDLE AGES AND EARLY MODERN ERA

Throughout the 8th century, physicians noticed patterns in patients with diabetes, such as skin infections, rodent ulcers, and eye problems. These complications led to a growing recognition of a distinct medical condition.[5–8]

Aretaeus of Cappadocia, a Greek physician, was one of the earliest known physicians to describe a condition closely resembling diabetes, referring to it as “diabetes” in his writings. He emphasized the symptoms and manifestations of diabetes, including excessive thirst, frequent urination, weight loss, and fatigue. Aretaeus also recognized the chronic nature of the pathology, suggesting that diabetes is a kidney disease.[5,7–9]

Avicenna, a Persian polymath and physician, provided a detailed description of diabetes and its complications, highlighting the symptoms, characteristics, and progression of thedisease.[5–8]

Maimonides, a medieval Jewish philosopher and physician, further expanded upon the understanding of diabetes, providing detailed descriptions of the disease’s symptoms and progression, including the symptoms of acidosis.[5–8]

The term “diabetes mellitus” comes from the Latin word for “honey-sweet”, which was added to the name of diabetes to describe the characteristic sweetness of diabetic patients' urine. Thomas Willis, an English physician, anatomist, and neurologist, was known as the “Father of Neurology” for his significant contributions to the understanding of the nervous system. In 1674, Willis conducted an experiment that significantly advanced the understanding of diabetes by tasting the urine of a diabetic patient, confirming its sweetness. This experiment marked an important turning point in diabetes research, providing concrete proof of the sweet taste of diabetic urine and establishing a more concrete link between diabetes symptoms and the presence of sugar in the urine.[5–8]

John Rollo, a Scottish physician and chemist, made significant contributions to the understanding and early management of diabetes. He distinguished Type 1 diabetes and Type 2 diabetes, identifying patients with "melituria" and those with slower onset symptoms. Rollo's exploration of dietary interventions in diabetes management, such as reducing starchy and sugary foods, foreshadowed modern approaches to managing diabetes through diet. Although not a cure, his insights influenced subsequent research and treatment approaches.[6]

19TH CENTURY ADVANCEMENTS

The 19th century saw significant advancements in understanding diabetes, with Claude Bernard's groundbreaking research on glucose regulation. His studies on the liver's role in glucose homeostasis and its capacity to produce and store glucose laid the foundation for understanding the dysregulation of glucose metabolism in diabetes. This knowledge advanced our understanding of the complex interplay between organs and hormones in maintaining proper blood sugar levels, a cornerstone of modern diabetes research and management.[5,7,8]

In the late 1800s, German researchers Paul Langerhans and Joseph von Mering independently identified the pancreatic islets, setting the stage for further investigations into the relationship between the pancreas and diabetes. After performing a pancreatectomy on a dog, Minkowski discovered polyuria due to phlorizin treatment. They repeated the experiment in three more dogs without sugar in their urine, and implanted a small portion of the pancreas subcutaneously in depancreatized dogs, demonstrating that the pancreas is a crucial gland for maintaining glucose homeostasis.[5–8]

INSULIN AND THE 20TH CENTURY

The early 20th century marked a significant moment in diabetes history with the discovery of insulin. Canadian physician Frederick Banting and medical student Charles Best, along with colleagues John Macleod and James Collip, made history by isolating insulin from the pancreas of dogs and treating a young boy with diabetes in 1922. This groundbreaking breakthrough heralded a new era in diabetes management, extending and saving countless lives.[5–8,10,11]

Romanian physician and professor Nicolae Paulescu played a crucial role in the discovery of insulin, conducting groundbreaking research on the pancreas and its role in glucose regulation. Paulescu's work involved the isolation of "pancreine", a substance with glucose-lowering properties. He published the results of his studies in 1921 in the journal "Archives International des Physiologie".[11–17]

In 1885, Sir William Osler and Thomas Willis proposed a classification scheme that distinguished between two main forms of diabetes: diabetes mellitus and diabetes insipidus. Within the category of diabetes mellitus, Osler and Willis, along with French researchers Apollinaire Bouchardat and E. Lancereux, further categorized the condition into two types: diabetes mellitus minor/maigre (Type 1) and diabetes mellitus major/gras (Type 2). This classification revolutionized treatment approaches and paved the way for tailored interventions.[5–8,10]

MODERN ERA AND BEYOND

In the 20th and 21st centuries, diabetes care has experienced numerous discoveries, innovations, and advancements. Home blood glucose monitoring, oral antidiabetic medications, and insulin analogs have enabled individuals to actively manage their condition. Continuous glucose monitoring (CGM) systems and insulin pumps have further improved the quality of life for those with diabetes.

Dr. Arnold Kadish designed the first insulin pump in 1963, and later, MiniMed introduced insulin-friendly tubing and insulin-friendly pumps. Over 140 trials are conducted on closed loop pumps, including intra-peritoneal or dual hormone pumps. [18–25]

Research has also explored genetic predispositions, environmental influences, and lifestyle factors contributing to diabetes development. Public health campaigns and educational initiatives aim to raise awareness about diabetes prevention and early detection, emphasizing the importance of healthy lifestyle choices.[26–30]

The future holds promise as cutting-edge research explores regenerative medicine, islet cell transplantation, and potential cures through gene therapy. A multidisciplinary approach blending genetics, immunology, and personalized medicine may yield solutions that redefine the landscape of diabetes management.[31–33]

MISCONCEPTIONS AND SHIFTING PARADIGMS

One of the most significant contributors to conceptual interferences in diabetology is the persistence of misconceptions. Traditional notions, such as diabetes being solely a "sugar disease", have hindered a comprehensive understanding of the disorder.[34] Over time, scientific understanding of diabetes has evolved to embrace its multifaceted nature, including genetic predispositions, hormonal imbalances, and intricate interactions with other metabolic conditions.[5,24–26,28,30–32]

Conceptual shifts have also been fueled by the recognition of different diabetes subtypes, such as type 1, type 2, gestational diabetes, and latent autoimmune diabetes in adults (LADA).[1,34]The blurred lines between these subtypes often lead to diagnostic challenges and may influence treatment decisions. Moreover, recent research has unearthed the concept of "double diabetes", where individuals exhibit characteristics of both type 1 and type 2 diabetes, further blurring the lines between traditional classifications.[35,36]

PATIENT VARIABILITY AND INDIVIDUALIZED CARE

Conceptual interferences in diabetology are amplified by the immense variability seen among diabetic patients. Factors such as genetics, lifestyle, psychological profile, age, and comorbidities contribute to this diversity.[1,2,37] While this variability underscores the importance of individualized care, it also introduces challenges in establishing universal treatment guidelines.[38]

The one-size-fits-all approach to diabetes management may not be suitable in the face of this diversity. Tailoring treatment plans to suit a patient's unique circumstances, preferences, and goals is essential. This approach requires healthcare practitioners to transcend rigid protocols and actively engage in shared decision-making with patients, taking into account their individual needs and values.[27,30,38]

EXPANDING HORIZONS: THE EVOLUTION OF DIABETOLOGY-ORIGINATED DRUGS IN DIVERSE MEDICAL SPECIALTIES

THE PIONEERS: SGLT-2 INHIBITORS AND GLP-1 AGONISTS

Two prominent classes of drugs that illustrate this evolution are SGLT-2 inhibitors and GLP-1 agonists. Originally created to manage blood glucose levels in individuals with diabetes, these drugs have ventured beyond diabetology to leave a significant mark in various medical domains.[39–52]

CARDIOLOGY: PROTECTING HEARTS BEYOND SUGAR CONTROL

SGLT-2 inhibitors, once solely associated with glucose regulation, have found their way into cardiology. These drugs have exhibited cardiovascular benefits that extend beyond glycemic control. Clinical trials have shown reductions in heart failure hospitalizations and cardiovascular mortality in patients with or without diabetes, being used as therapy in patients with heart failure and reduced or preserved ejection fraction. The mechanism of action involves inhibiting glucose reabsorption in the kidneys, leading to increased glycosuria and osmotic diuresis. This diuretic effect reduces cardiac strain, making SGLT-2 inhibitors invaluable in managing heart failure patients.[40–43,45,49,52]

Furthermore, GLP-1 agonists (Liraglutide, Semaglutide, Dulaglutide, Exenatide) start to show their potential to mitigate cardiovascular risks.[53–58]

NEPHROLOGY: RENAL PRESERVATION UNVEILED

Another specialty that has reaped the rewards of diabetology-originated drugs is nephrology. The same SGLT-2 inhibitors that alleviate hyperglycemia have demonstrated renoprotective effects. By attenuating glomerular hyperfiltration and reducing albuminuria, these drugs slow down the progression of diabetic kidney disease. This novel application has altered the landscape of renal care, offering hope to patients with compromised kidney function.[44,46,47,49]

OBESITY AND ENDOCRINOLOGY: GLP-1 AGONISTS TAKE CENTER STAGE

GLP-1 agonists, known for their role in enhancing insulin secretion and inhibiting glucagon release, have also transcended their initial diabetic context. In the realm of obesity management, these drugs have emerged as potent allies. By suppressing appetite and promoting satiety, GLP-1 agonists facilitate weight loss, offering a valuable tool in the fight against obesity. They slow stomach emptying, leading to longer fullness and reduced calorie intake. GLP-1 agonists may also influence energy expenditure, potentially contributing to weight loss. Clinical trials show significant weight loss in individuals with obesity, even without diabetes, although the degree of weight loss varies among different GLP-1 agonists. Furthermore, GLP-1 agonists have gained attention for their potential benefits in addressing certain aspects of PCOS and infertility. Studies suggest that GLP-1 agonists may improve ovulation and fertility in women with PCOS, restoring regular menstrual cycles and increasing ovulation chances. Additionally, GLP-1 agonists may have anti-inflammatory effects, potentially aiding in managing PCOS symptoms.[46–49,59–61]

NEUROLOGY: EMERGING AVENUES FOR EXPLORATION

The far-reaching implications of diabetology-originated drugs extend even to neurology. Recent studies have suggested that SGLT-2 inhibitors could hold promise in the realm of neuroprotection. With their potential to modulate neuroinflammation and oxidative stress, by blocking microglial activation of reactive astrocytes, these drugs are being explored as potential agents in managing neurodegenerative disorders, such as Alzheimer's disease or Parkinson's disease.[62–66]

METFORMIN'S MULTIFACETED POTENTIAL

Metformin has been used to manage symptoms of polycystic ovary syndrome (PCOS), a condition characterized by hormonal imbalances and reproductive difficulties. It can improve insulin sensitivity, regulate hormones, and improve ovulation and fertility in women with PCOS. In addition, some studies have found antineoplastic benefits. Metformin's potential anticancer effects include affecting cellular processes, cancer prevention, and adjunct therapy. It is also being explored as a potential adjunct therapy in combination with traditional cancer treatments. Metformin's potential role in aging and extending lifespan is also being explored, targeting aging processes, cellular metabolism, and improving mitochondrial function. Clinical trials are currently being conducted to investigate metformin's effects on aging in humans, focusing on markers of aging and extending the period of healthy living.[67–72]

TECHNOLOGICAL ADVANCEMENTS AND DIAGNOSTIC COMPLEXITY

The advent of cutting-edge technologies has revolutionized the field of diabetology, enabling more accurate monitoring and precise interventions. However, these advancements also bring forth new challenges in interpretation and integration. Continuous glucose monitoring (CGM), insulin pumps, and artificial pancreas systems offer unprecedented insights into a patient's glucose dynamics.[18–25,31] However, healthcare providers must navigate the influx of data and comprehend their implications accurately.

Furthermore, the diagnostic complexity associated with some diabetes subtypes can confound healthcare practitioners. For instance, distinguishing between type 1 diabetes and LADA may be challenging due to overlapping clinical and laboratory features.[1,28,30,34] Such complexities demand a multidisciplinary approach, involving endocrinologists, immunologists, and geneticists, among others, to arrive at accurate diagnoses and effective treatment plans.

ADDRESSING CONCEPTUAL INTERFERENCES

Education and Awareness: Combating misconceptions requires a concerted effort to educate both healthcare professionals and the general public. Raising awareness about the multifactorial nature of diabetes and its evolving classifications can promote accurate understanding.

Multidisciplinary Collaboration: Embracing a team-based approach that involves endocrinologists, dietitians, psychologists, and genetic counselors can enhance patient care by integrating diverse perspectives.

Personalized Medicine: Harnessing the power of data analytics and artificial intelligence can aid in tailoring treatments based on individual patient profiles, optimizing outcomes.

Research and Innovation: Continued research into diabetes subtypes, pathophysiology, and emerging therapies is crucial for staying ahead of conceptual shifts and effectively managing the disorder.

CONCLUSIONS

The tapestry of diabetes chronology weaves a narrative of relentless inquiry, collaboration, and progress. From the cryptic observations of ancient civilizations to the groundbreaking discovery of insulin and the contemporary landscape of advanced diabetes management, the journey has been marked by tenacity and unwavering determination. As science and technology continue to illuminate the path forward, the legacy of those who have dedicated their lives to understanding and combating diabetes mellitus serves as a beacon of hope for a future where the boundaries of this condition may one day be transcended. This evolution serves as a reminder that innovation knows no bounds and that solutions to complex medical challenges often lie in unexpected places. Conceptual interferences in diabetology stem from a complex interplay of misconceptions, shifting paradigms, patient variability, and technological advancements. Navigating these interferences demands a holistic approach that embraces education, collaboration, personalization, and innovation. As our understanding of diabetes continues to evolve, addressing these challenges will pave the way for improved patient care, enhanced scientific progress, and ultimately, better outcomes in the management of this global health concern. By unraveling the intricacies of conceptual interferences, we empower healthcare professionals to provide more effective, tailored care to individuals living with diabetes.

REFERENCES

1. Association AD. *Diagnosis and Classification of Diabetes Mellitus*. *Diabetes Care*. **2013**;*36*(*Suppl 1*):*S67*.
2. Cloete L. *Diabetes mellitus: an overview of the types, symptoms, complications and management*. *Nursing standard (Royal College of Nursing (Great Britain) : 1987)*. **2022**;*37*(*1*):*61–66*.
3. Anon. *World Health Organization: Global health estimates:... - Google Academic*.
4. Mathers CD, Loncar D. *Projections of Global Mortality and Burden of Disease from 2002 to 2030*. *PLoS Medicine*. **2006**;*3*(*11*):*2011–2030*.
5. Karamanou M, Protogerou A, Tsoucalas G, Androutsos G, Poulakou-Rebelakou E. *Milestones in the history of diabetes mellitus: The main contributors*. *World Journal of Diabetes*. **2016**;*7*(*1*):*1*.
6. Vecchio I, Tornali C, Bragazzi NL, Martini M. *The discovery of insulin: An important milestone in the history of medicine*. *Frontiers in Endocrinology*. **2018**;*9*:*343536*.
7. Nutton V. *Ancient Medicine*. *Ancient Medicine*. **2004**:*1–486*.
8. Anon. *Milestones in diabetes*.
9. Laios K, Karamanou M, Saridaki Z, Androutsos G. *Aretaeus of Cappadocia and the first description of diabetes*. *Hormones*. **2012**;*11*(*1*):*109–113*.
10. Forsham PH. *Milestones in the 60-Year History of Insulin: (1922–1982)*. *Diabetes Care*. **1982**;*5*(*Supplement_2*):*1–3*.
11. Tilinca MC, Detesan O, Schmiedt RA, Kovacs BI, Custura LM, Tilinca RM, Abalasei B, Florea A. *The multidimensional evolution of insulin from the molecular to the therapeutic level*. *Proc. Rom. Acad., Series B*. **2021**;*23*(*3*):*223–284*.
12. Haulica I. *Profesorul Nicolae C. Paulescu--adevaratul descoperitor al insulinei*. *Revista medico-chirurgicala a Societații de Medici şi Naturalişti din Iaşi*. **2001**;*105*(*3*):*602–605*.
13. Laron Z. *Nicolae C. Paulescu - Scientist and politician*. *Israel Medical Association Journal*. **2008**;*10*(*7*):*491–493*.
14. Ionescu-Tirgoviste C, Buda O. *Nicolae Constantin Paulescu: The first explicit description of the internal secretion of the Pancreas*. *AMHA - Acta Medico-Historica Adriatica*. **2017**;*15*(*2*):*303–322*.
15. Benția D, Saceleanu MV, Marinescu AA, Ciurea A V. *Centenary of Insulin Discovery (1921-2021): Nicolae Paulescu's Original Contributions*. *Acta Endocrinologica (Bucharest)*. **2021**;*17*(*3*):*406*.
16. Ionescu-Tirgoviste C, Buda O. *Nicolae Constantin Paulescu: the first explicit description of the internal secretion of the pancreas*. *Acta medico-historica adriatica : AMHA*. **2017**;*15*(*2*):*303–322*.
17. de Leiva-Hidalgo A, de Leiva-Pérez A. *On the occasion of the centennial of the Nobel Prize in Physiology or Medicine, 1923: Nicolae C. Paulescu-between scientific creativity and political fanatism*. *Acta diabetologica*. **2023**.
18. Ghosh S, Collier A. *Inhaled insulins*. *Postgraduate Medical Journal*. **2007**;*83*(*977*):*178–181*.
19. Pickup JC, Keen H, Parsons JA, Alberti KG. *Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia*. *Br Med J*. **1978**;*1*(*6107*):*204–207*.
20. Pickup J, Keen H. *Continuous Subcutaneous Insulin Infusion at 25 YearsEvidence base for the expanding use of insulin pump therapy in type 1 diabetes*. *Diabetes Care*. **2002**;*25*(*3*):*593–598*.
21. Tamborlane W V., Sherwin RS, Genel M, Felig P. *Reduction to Normal of Plasma Glucose in Juvenile Diabetes by Subcutaneous Administration of Insulin with a Portable Infusion Pump*. *http://dx.doi.org/10.1056/NEJM197903153001101*. **2010**;*300*(*11*):*573–578*.
22. Albisser AM, Leibel BS, Ewart TG, Davidovac Z, Botz CK, Zingg W. *An Artificial Endocrine Pancreas*. *Diabetes*. **1974**;*23*(*5*):*389–396*.
23. Pfeiffer EF, Thum C, Clemens AH. *The artificial beta cell: a continuous control of blood sugar by external regulation of insulin infusion (glucose controlled insulin infusion system)*. *Hormone and Metabolic Research*. **1974**;*6*(*5*):*339–342*.

24. Mirouze J, Selam JL, Pham TC, Cavadore D. *Evaluation of exogenous insulin homoeostasis by the artificial pancreas in insulin-dependent diabetes*. *Diabetologia*. **1977**;*13*(*3*):*273–278*.
25. Kraegen EW, Campbell L V., Chia YO, Meier H, Lazarus L. *Control of Blood Glucose in Diabetics using an Artificial Pancreas*. Australian and New Zealand Journal of Medicine*. **1977**;*7*(*3*):*280–286*.
26. Wu Y, Ding Y, Tanaka Y, Zhang W. *Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention*. *International Journal of Medical Sciences*. **2014**;*11*(*11*):*1185*.
27. Gruss SM, Nhim K, Gregg E, Bell M, Luman E, Albright A. *Public Health Approaches to Type 2 Diabetes Prevention: the US National Diabetes Prevention Program and Beyond*. *Current Diabetes Reports*. **2019**;*19*(*9*).
28. Guasch-Ferré M, Hruby A, Toledo E, Clish CB, Martínez-González MA, Salas-Salvadó J, Hu FB. *Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis*. *Diabetes care*. **2016**;*39*(*5*):*833–846*.
29. DiMeglio LA, Evans-Molina C, Oram RA. *Type 1 diabetes*. *Lancet (London, England)*. **2018**;*391*(*10138*):*2449*.
30. Gillespie KM. *Type 1 diabetes: pathogenesis and prevention*. *CMAJ : Canadian Medical Association Journal*. **2006**;*175*(*2*):*165*.
31. Gamble A, Pepper AR, Bruni A, Shapiro AMJ. *The journey of islet cell transplantation and future development*. *Islets*. **2018**;*10*(*2*):*80*.
32. Chellappan DK, Sivam NS, Teoh KX, Leong WP, Fui TZ, Chooi K, Khoo N, Yi FJ, Chellian J, Cheng LL, Dahiya R, Gupta G, Singhvi G, Nammi S, Hansbro PM, et al. *Gene therapy and type 1 diabetes mellitus*. *Biomedicine & Pharmacotherapy*. **2018**;*108*:*1188–1200*.
33. Everett E, Mathioudakis N. *Update on management of diabetic foot ulcers*. *Annals of the New York Academy of Sciences*. **2018**;*1411*(*1*):*153*.
34. Patil R, Nasrin Nisha A, Datta SS, Boratne A V., Lokeshmaran. *Popular Misconceptions Regarding the Diabetes Management: Where Should We Focus Our Attention? Journal of Clinical and Diagnostic Research : JCDR*. **2013**;*7*(*2*):*287*.
35. Cleland SJ, Fisher BM, Colhoun HM, Sattar N, Petrie JR. *Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks? Diabetologia*. **2013**;*56*(*7*):*1462*.
36. Kietsiriroje N, Pearson S, Campbell M, Ariëns RAS, Ajjan RA. *Double diabetes: A distinct high-risk group? Diabetes, Obesity and Metabolism*. **2019**;*21*(*12*):*2609–2618*.
37. The Lancet. *Diabetes: a dynamic disease*. *The Lancet*. **2017**;*389*(*10085*):*2163*.
38. Powell PW, Corathers SD, Raymond J, Streisand R. *New Approaches to Providing Individualized Diabetes Care in the 21st Century*. *Current diabetes reviews*. **2015**;*11*(*4*):*222*.
39. Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, Tunnicliffe D, Ruospo M, Natale P, Saglimbene V, Nicolucci A, Johnson DW, Tonelli M, Rossi MC, Badve S V., et al. *Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials*. *The BMJ*. **2021**;*372*.
40. McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Diez M, Nicolau J, Katova T, et al. *A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)*. *European journal of heart failure*. **2019**;*21*(*5*):*665–675*.
41. Giaccari A, Pontremoli R, Perrone Filardi P. *SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice*. *International journal of cardiology*. **2022**;*351*:*66–70*.
42. Tomasoni D, Fonarow GC, Adamo M, Anker SD, Butler J, Coats AJS, Filippatos G, Greene SJ, McDonagh TA, Ponikowski P, Rosano G, Seferovic P, Vaduganathan M, Voors AA, Metra M. *Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction*. *European journal of heart failure*. **2022**;*24*(*3*):*431–441*.
43. Pandey AK, Dhingra NK, Hibino M, Gupta V, Verma S. *Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis*. *ESC heart failure*. **2022**;*9*(*2*):*942–946*.
44. Baigent C, Emberson JR, Haynes R, Herrington WG, Judge P, Landray MJ, Mayne KJ, Ng SYA, Preiss D, Roddick AJ, Staplin N, Zhu D, Anker SD, Bhatt DL, Brueckmann M, et al. *Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials*. *Lancet (London, England)*. **2022**;*400* (*10365*):*1788–1801*.
45. Cao Y, Li P, Li Y, Han Y. *Sodium-glucose cotransporter-2 inhibitors in heart failure: an updated meta-analysis*. *ESC heart failure*. **2022**;*9*(*3*):*1942–1953*.
46. Yamada T, Wakabayashi M, Bhalla A, Chopra N, Miyashita H, Mikami T, Ueyama H, Fujisaki T, Saigusa Y, Yamaji T, Azushima K, Urate S, Suzuki T, Abe E, Wakui H, et al. *Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis*. *Cardiovascular diabetology*. **2021**;*20*(*1*).
47. Zhang Y, Jiang L, Wang J, Wang T, Chien C, Huang W, Fu X, Xiao Y, Fu Q, Wang S, Zhao J. *Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease*. *Cardiovascular diabetology*. **2022**;*21*(*1*).
48. Ma H, Lin YH, Dai LZ, Lin CS, Huang Y, Liu SY. *Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis*. *BMJ open*. **2023**;*13*(*3*).
49. Puglisi S, Rossini A, Poli R, Dughera F, Pia A, Terzolo M, Reimondo G. *Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System*. *Frontiers in endocrinology*. **2021**;*12*.
50. Androutsakos T, Nasiri-Ansari N, Bakasis AD, Kyrou I, Efstathopoulos E, Randeva HS, Kassi E. *SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection*. *International journal of molecular sciences*. **2022**;*23*(*6*).

51. Pereira MJ, Eriksson JW. *Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity*. *Drugs*. **2019**;*79*(*3*):*219–230*.
52. Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, Goh SY, Thuresson M, Chen H, Surmont F, Hammar N, Fenici P, Cavender MA, Fu AZ, et al. *Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study*. *Journal of the American College of Cardiology*. **2018**;*71*(*23*):*2628–2639*.
53. Ma X, Liu Z, Ilyas I, Little PJ, Kamato D, Sahebka A, Chen Z, Luo S, Zheng X, Weng J, Xu S. *GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential*. *International journal of biological sciences*. **2021**;*17*(*8*):*2050–2068*.
54. Andrikou E, Tsioufis C, Andrikou I, Leontsinis I, Tousoulis D, Papanas N. *GLP-1 receptor agonists and cardiovascular outcome trials: An update*. *Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese*. **2019**;*60*(*6*):*347–351*.
55. SP M, GH D, K B-F, P K, JF M, MA N, SE N, S P, NR P, LS R, WM S, M S, B Z, RM B, JB B. *Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes*. *The New England journal of medicine*. **2016**;*375*(*4*):*101*.
56. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T. *Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes*. *The New England journal of medicine*. **2016**;*375*(*19*):*1834–1844*.
57. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riddle MC, Rydén L, Xavier D, Atisso CM, Avezum A, Basile J, Chung N, Conget I, et al. *Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide*. *Diabetes, obesity & metabolism*. **2018**;*20*(*1*):*42–49*.
58. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, et al. *Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes*. *The New England journal of medicine*. **2017**;*377*(*13*):*1228–1239*.
59. Grill HJ. *A Role for GLP-1 in Treating Hyperphagia and Obesity*. *Endocrinology*. **2020**;*161*(*8*):*1–14*.
60. Cena H, Chiovato L, Nappi RE. *Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists*. *The Journal of clinical endocrinology and metabolism*. **2020**;*105*(*8*).
61. Drucker DJ. *GLP-1 physiology informs the pharmacotherapy of obesity*. *Molecular metabolism*. **2022**;*57*.
62. Park JS, Kam TI, Lee S, Park H, Oh Y, Kwon SH, Song JJ, Kim D, Kim H, Jhaldiyal A, Na DH, Lee KC, Park EJ, Pomper MG, Pletnikova O, et al. *Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer's disease*. *Acta neuropathologica communications*. **2021**;*9*(*1*).
63. Reich N, Hölscher C. *The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review*. *Frontiers in neuroscience*. **2022**;*16*.
64. Yun SP, Kam TI, Panicker N, Kim S, Oh Y, Park JS, Kwon SH, Park YJ, Karuppagounder SS, Park H, Kim S, Oh N, Kim NA, Lee S, Brahmachari S, et al. *Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease*. *Nature medicine*. **2018**;*24*(*7*):*931–938*.
65. Hölscher C. *Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders*. *British journal of pharmacology*. **2022**;*179*(*4*):*695–714*.
66. Mulvaney CA, Duarte GS, Handley J, Evans DJW, Menon S, Wyse R, Emsley HCA. *GLP-1 receptor agonists for Parkinson's disease*. *The Cochrane database of systematic reviews*. **2020**;*7*(*7*).
67. Mohammed I, Hollenberg MD, Ding H, Triggle CR. *A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan*. *Frontiers in endocrinology*. **2021**;*12*.
68. Cejuela M, Martin-Castillo B, Menendez JA, Pernas S. *Metformin and Breast Cancer: Where Are We Now?* *International journal of molecular sciences*. **2022**;*23*(*5*).
69. Chen S, Gan D, Lin S, Zhong Y, Chen M, Zou X, Shao Z, Xiao G. *Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms*. *Theranostics*. **2022**;*12*(*6*):*2722–2740*.
70. Coyle C, Cafferty FH, Vale C, Langley RE. *Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis*. *Annals of oncology : official journal of the European Society for Medical Oncology*. **2016**;*27*(*12*):*2184–2195*.
71. Foretz M, Guigas B, Viollet B. *Metformin: update on mechanisms of action and repurposing potential*. *Nature reviews. Endocrinology*. **2023**;*19*(*8*).
72. Kamarudin MNA, Sarker MMR, Zhou JR, Parhar I. *Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects*. *Journal of experimental & clinical cancer research : CR*. **2019**;*38*(*1*).